The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.

The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.

The T lymphocytes are the most important effector cells in immunotherapy of cancer. The conceptual objective for developing the tumor targeted superantigen (TTS) ABR-217620 (naptumomab estafenatox, 5T4Fab-SEA/E-120), now in phase 3 studies for advanced renal cell cancer, was to selectively coat tumo...

Full description

Bibliographic Details
Main Authors: Gunnar Hedlund, Helena Eriksson, Anette Sundstedt, Göran Forsberg, Bent K Jakobsen, Nicholas Pumphrey, Karin Rödström, Karin Lindkvist-Petersson, Per Björk
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3806850?pdf=render

Internet

http://europepmc.org/articles/PMC3806850?pdf=render

Similar Items